%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Abuduaini, T.
%A Roy, V.
%A Marlet, J.
%A Gaudy-Graffin, C.
%A Brand, D.
%A Baronti, Cécile
%A Touret, F.
%A Coutard, B.
%A McBrayer, T. R.
%A Schinazi, R. F.
%A Agrofoglio, L. A.
%T Synthesis and antiviral evaluation of (1,4-disubstituted-1,2,3-triazol)-(e)-2-methyl-but-2-Enyl nucleoside phosphonate prodrugs
%D 2021
%L fdi:010081107
%G ENG
%J Molecules
%K nucleosides ; olefin cross metathesis ; ultrasound ; copper-catalyzed ; azide-alkyne cycloaddition (CuAAC) ; antiviral properties ; HBV ; HIV ; SARS-CoV-2
%M ISI:000628427000001
%N 5
%P 1493 [18 ]
%R 10.3390/molecules26051493
%U https://www.documentation.ird.fr/hor/fdi:010081107
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2021-05/010081107.pdf
%V 26
%W Horizon (IRD)
%X A series of hitherto unknown (1,4-disubstituted-1,2,3-triazol)-(E)-2-methyl-but-2-enyl nucleosides phosphonate prodrugs bearing 4-substituted-1,2,3-triazoles were prepared in a straight approach through an olefin acyclic cross metathesis as the key synthetic step. All novel compounds were evaluated for their antiviral activities against HBV, HIV and SARS-CoV-2. Among these molecules, only compound 15j, a hexadecyloxypropyl (HDP)/(isopropyloxycarbonyl-oxymethyl)-ester (POC) prodrug, showed activity against HBV in Huh7 cell cultures with 62% inhibition at 10 mu M, without significant cytotoxicity (IC50 = 66.4 mu M in HepG2 cells, IC50 = 43.1 mu M in HepG2 cells) at 10 mu M.
%$ 020 ; 050 ; 052